eRAM
encyclopedia of Rare Disease Annotation for Precision Medicine
| Disease | non-alcoholic fatty liver disease |
| Comorbidity | |obesity |
| Sentences | 164 |
| PubMedID- 20043126 | These findings suggest that excess long-term feeding of a diet similar to the synthetic diet used in our study leads to hepatic fibrosis during the development of nafld in patients with obesity or type 2 diabetes. |
| PubMedID- 25003952 | Background & aims: non-alcoholic fatty liver disease (nafld) is strongly associated with obesity and type 2 diabetes. |
| PubMedID- 25911909 | Conclusion: development of nafld are associated with obesity and excess body weight, phenomenon of leptinresistance arises to patients with obesity and can be considered as predictor of the development and progression of nafld among this category of patients. |
| PubMedID- 21364120 | Nonalcoholic fatty liver disease (nafld) is associated with obesity, insulin resistance, and inflammatory disorders. |
| PubMedID- 22934189 | nafld is often associated with obesity, type 2 diabetes mellitus, and dyslipidemia and is also regarded as a hepatic manifestation of metabolic syndrome [4]. |
| PubMedID- 24151620 | nafld associated with obesity and hyperlipidemia encompasses a spectrum of histopathology, ranging from steatosis to cirrhosis. |
| PubMedID- 25663786 | Aim: to investigate whether central obesity is associated with nonalcoholic fatty liver disease (nafld) formation after adjusting for general obesity. |
| PubMedID- 24737534 | Background: morbid obesity is strongly associated with nonalcoholic fatty liver disease. |
| PubMedID- 24019886 | In 90% of cases obesity is associated with non-alcoholic fatty liver disease (nafld), an accumulation of intra-hepatic triglycerides that is often considered the hepatic manifestation of insulin resistance. |
| PubMedID- 20221393 | Background: non-alcoholic steatohepatitis (nash) is a serious form of non-alcoholic fatty liver disease (nafld), associated with obesity and insulin resistance. |
| PubMedID- 25905166 | Furthermore, serum igf-i levels decline with normal aging, and tend to be low in obesity and in patients with non-alcoholic fatty liver disease. |
| PubMedID- 24367371 | Restricting these bacteria requires il-18 and failure promotes ccl5-dependent colonic inflammation and increased tlr4 and tlr9 agonist influx into the portal vein, which eventually causes non-alcoholic fatty liver disease (nafld), a comorbidity associated with obesity, metabolic syndrome, and nash progression (144, 230). |
| PubMedID- 25143715 | Interestingly, we showed that in contrast to the general population, where nafld is associated with obesity, in the present study, there was no statistically significant association between nafld and overnutrition in elderly hd patients. |
| PubMedID- 24895482 | (3) nafld is closely associated with central adiposity, obesity, insulin resistance, metabolic syndrome, and type 2 diabetes, and it is currently considered an important public health issue worldwide. |
| PubMedID- 23320150 | Evidence is now accumulating that nafld is associated with obesity and diabetes and may serve as a predictor of cardiovascular disease (cvd). |
| PubMedID- 22829877 | nafld is associated with obesity and insulin resistance [7]. |
| PubMedID- 22720061 | non-alcoholic fatty liver disease is associated with obesity and considered an inflammatory disease. |
| PubMedID- 24517247 | obesity is associated with non-alcoholic fatty liver disease (nafld) [24], and resolution of nafld has been proven after bariatric surgery [25]. |
| PubMedID- 25767880 | Many lines of evidence indicate that nafld is associated with obesity, insulin resistance and metabolic syndrome (mets). |
| PubMedID- 26341254 | Aim: nonalcoholic fatty liver disease (nafld) is associated with obesity and affects roughly 10% of children. |
| PubMedID- 25484079 | nonalcoholic fatty liver disease (nafld), typically associated with overnutrition and obesity, is one of the most common liver diseases both in the us and worldwide. |
| PubMedID- 25278690 | Viral hepatitis, alcohol abuse, and exposure to hepatotoxins are major risk factors, but nonalcoholic fatty liver disease (nafld) associated with obesity, insulin resistance, and type 2 diabetes, is an increasingly recognized trigger, especially in developed countries. |
| PubMedID- 22811888 | obesity is associated with nonalcoholic fatty liver disease (nafld) that encompasses a spectrum ranging from simple steatosis to nonalcoholic steatohepatitis (nash), fibrosis, and cirrhosis. |
| PubMedID- 24269922 | Iron deficiency in patients with nonalcoholic fatty liver disease is associated with obesity, female gender, and low serum hepcidin. |
| PubMedID- 19882375 | Background: although nonalcoholic fatty liver disease (nafld) is associated with visceral obesity, the relationship between visceral fat accumulation and skeletal muscle steatosis in patients with nafld has not been established. |
| PubMedID- 20188144 | Background: non-alcoholic fatty liver disease (nafld) is associated with obesity, insulin resistance and hepatic steatosis. |
| PubMedID- 20953409 | Human nafld is mostly associated with obesity and diabetes. |
| PubMedID- 24336007 | Conclusions: the results of the study suggest that nafld is associated with visceral obesity and low hdl-cholesterol in patients with type 2 diabetes. |
| PubMedID- 22690340 | The most important causes leading to hcc are the hbv and hcv infections, heavy alcohol consumption, aflatoxin b1, age and gender (males are more susceptible than females), race (asian and african over 20 years old), tobacco consumption, obesity associated with nonalcoholic fatty liver disease, and the increase of the diabetes ii mellitus (that rises the risk factor between 2 and 3), genetic hemochromatosis, primary biliary cirrhosis, and alpha1-antitrypsin deficiency and autoimmune hepatitis [1, 2, 5–32]. |
| PubMedID- 20078219 | nafld is closely associated with obesity and is most closely linked with insulin resistance; the current western diet, high in saturated fats and fructose, plays a significant role. |
| PubMedID- 20818807 | Although it is well established that insulin resistance, glucose intolerance and obesity occur frequently with non-alcoholic fatty liver disease (nafld), it is now becoming apparent that hypoxia might also be important in the development of nafld, and it is recognized that there is increased risk of nafld with osa. |
| PubMedID- 25456868 | Nonalcoholic fatty liver disease (nafld) is associated with obesity and insulin resistance and has been linked with increased cardiovascular risk. |
| PubMedID- 24763757 | In conclusion, a proportion of nafld patients without morbid obesity, which is similar of that of matched subjects from the general population without ultrasonographic steatosis, is at high risk for osas with excessive daytime sleepiness, as detected by bq and ess combined positivity. |
| PubMedID- 23867312 | Background & aims: the development and progression of non-alcoholic fatty liver disease are associated with aging, obesity, and type 2 diabetes. |
| PubMedID- 25939720 | Background: obesity is associated with non-alcoholic fatty liver disease (nafld), and the patatin-like phospholipase 3 (pnpla3) rs738409 (ile148met, c>g) gene polymorphism is one of the most important genetic determinants of nafld. |
| PubMedID- 22468076 | Nonalcoholic fatty liver disease (nafld) is associated with obesity, insulin resistance, and type 2 diabetes. |
| PubMedID- 25841911 | Majority of cases of hcc are due to chronic viral hepatitis b and c infections; however non-alcoholic fatty liver disease, associated with obesity and diabetes emerges as an important risk factor for hcc, in particular in the developed countries. |
| PubMedID- 21604917 | Hepatic steatosis due to non-alcoholic fatty liver disease is associated with obesity, dyslipidemia, insulin resistance, and type 2 diabetes. |
| PubMedID- 20355232 | obesity is associated with insulin resistance, non-alcoholic fatty liver disease (nafld) and gallstones.high fat diets (unsaturated fats) rich in cholesterol have been demonstrated to produce not only gallstones but also nafld and insulin resistance. |
| PubMedID- 21198708 | nafld is closely associated with obesity and insulin resistance, and is now recognised to represent the hepatic manifestation of the metabolic syndrome. |
| PubMedID- 23390441 | Purpose: childhood obesity is associated with nonalcoholic fatty liver disease (nafld), and it has become one of the most common causes of childhood chronic liver diseases which significant as a cause of liver related mortality and morbidity in children in the united states. |
| PubMedID- 25031864 | According to our study as well as the previous ones, it seems that non-alcoholic fatty liver associated with obesity is now well established in children as a major cause of chronic liver disease, and it is the same in asia and europe, among different countries. |
| PubMedID- 21240660 | Background: the prevalence of non-alcoholic fatty liver disease (nafld) in obesity is very high. |
| PubMedID- 20413174 | Background & aims: obesity induced, non-alcoholic fatty liver disease (nafld), is now the major cause in affluent countries, of the spectrum of steatosis-to-cirrhosis. |
| PubMedID- 24460705 | Conclusions: visceral obesity is associated with non-alcoholic fatty liver disease (nafld) and nash: we hypothesized that these conditions can influence adamts13 antigen and activity. |
| PubMedID- 25760690 | The most important causes leading to hcc are the hbv and hcv infections, heavy alcohol consumption, aflatoxin b1, gender (males are more susceptible than females), obesity associated with non-alcoholic fatty liver disease, and α1-antitrypsin deficiency (2). |
| PubMedID- 25601465 | Since nafld has been associated with obesity, insulin resistance, diabetes or alteration of lipid profiles, it is considered as the liver manifestation of metabolic syndrome. |
| PubMedID- 25974899 | Nonalcoholic fatty liver disease (nafld) is tightly associated with obesity and the metabolic syndrome in the united states and other western countries. |
| PubMedID- 20492695 | Visceral adipose tissue samples were obtained from 10 patients diagnosed with morbid obesity and one of the nafld spectrum diseases (n = 10) and nine lean patients with normal liver biopsies (n = 9). |
| PubMedID- 21238518 | It has been suggested that the high sensitivity c-reactive protein (hs-crp) is an obesity-independent surrogate marker of severity of nafld, especially development of non-alcoholic steato-hepatitis (nash), but this remains controversial. |